First Glucose Meter Cleared For Hospital ICUs As FDA Continues Work On Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA hopes the clearance of Nova Biomedical’s Nova StatStrip blood glucose monitor for hospitalized patients will help alleviate fears that increased regulatory standards will restrict critically ill patients’ access to point-of-care glucose testing. But the clearance does not necessarily settle the agency’s long-term policy plans for hospital-use glucose meters.
You may also be interested in...
US FDA Panel To Tackle Hospital Glucose Meter Accuracy Issue
FDA says it has become aware of large data sets that raise new questions about the level of accuracy that blood glucose meters can deliver in an intensive-care hospital setting using capillary blood samples. An advisory panel will be tasked March 30 with considering the issue and its impact on assessing risk-benefit of the devices in the hospital environment.
FDA Tempers Accuracy Standards For Hospital Glucose Meters In Final Guidance
The US agency finalized two closely watched guidance documents for blood glucose systems used in the hospital and at home. The guidance focusing on hospital point-of-care systems included a key revision of proposed accuracy standards from a 2014 draft guidance that had been broadly maligned as too tough.
Hospital Glucose Meter Standard Not Recognized By FDA, Agency Clarifies
FDA says a 2013 Clinical and Laboratory Standards Institute standard for hospital glucose testing was never meant to be recognized by the agency, despite a July listing.